EcoR1 Capital’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

EcoR1 Capital’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-837,885	Closed	-$20.5M	–	65
2020 Q2	$25.2M	Buy	+837,885	New	+$30.2M	1.86%	19
2019 Q1	–	Sell	-79,194	Closed	-$318K	–	56
2018 Q4	$318K	Sell	79,194 -200,806	-72%	-$1.21M	0.03%	52
2018 Q3	$1.88M	Buy	+280,000	New	+$2.67M	0.17%	44

Other funds holding CNST

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

EcoR1 Capital's CNST Position: Q3 2020 in Review

EcoR1 Capital sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2020, closing a stake of 837,885 shares — an estimated $20.5M sold.

EcoR1 Capital first reported a position in CNST in Q3 2018 and held it in 3 quarters. The position peaked at $25.2M in Q2 2020. 119 funds tracked by Wall St. Rank hold CNST as of Q3 2020.

EcoR1 Capital reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
EcoR1 Capital sold 837,885 Constellation Pharmaceuticals, Inc. shares in Q3 2020, an estimated $20.5M.
EcoR1 Capital first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 3 quarters.
EcoR1 Capital's Constellation Pharmaceuticals, Inc. position peaked at $25.2M in Q2 2020.
119 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2020.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.